Telos Capital Management Inc. Has $9.87 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Telos Capital Management Inc. lessened its holdings in Bristol-Myers Squibb (NYSE:BMY) by 26.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 192,259 shares of the biopharmaceutical company’s stock after selling 68,245 shares during the quarter. Bristol-Myers Squibb accounts for approximately 1.2% of Telos Capital Management Inc.’s investment portfolio, making the stock its 27th biggest position. Telos Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $9,865,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of BMY. Riversedge Advisors LLC increased its holdings in shares of Bristol-Myers Squibb by 3.2% in the third quarter. Riversedge Advisors LLC now owns 5,691 shares of the biopharmaceutical company’s stock worth $330,000 after purchasing an additional 178 shares during the period. Vicus Capital increased its holdings in shares of Bristol-Myers Squibb by 3.9% in the third quarter. Vicus Capital now owns 4,824 shares of the biopharmaceutical company’s stock worth $280,000 after purchasing an additional 179 shares during the period. Front Row Advisors LLC increased its holdings in shares of Bristol-Myers Squibb by 17.5% in the fourth quarter. Front Row Advisors LLC now owns 1,222 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 182 shares during the period. Cassia Capital Partners LLC increased its holdings in shares of Bristol-Myers Squibb by 2.3% in the third quarter. Cassia Capital Partners LLC now owns 7,931 shares of the biopharmaceutical company’s stock worth $460,000 after purchasing an additional 182 shares during the period. Finally, Lindbrook Capital LLC increased its holdings in shares of Bristol-Myers Squibb by 2.3% in the third quarter. Lindbrook Capital LLC now owns 8,060 shares of the biopharmaceutical company’s stock worth $468,000 after purchasing an additional 182 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on BMY. StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday. Wells Fargo & Company cut their target price on shares of Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 6th. Redburn Atlantic lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their target price for the stock from $77.00 to $54.00 in a research report on Tuesday, February 6th. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Finally, William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $61.12.

Bristol-Myers Squibb Trading Down 0.6 %

NYSE BMY traded down $0.28 during trading on Wednesday, hitting $47.98. 6,515,488 shares of the company’s stock traded hands, compared to its average volume of 15,773,822. The firm has a market cap of $97.24 billion, a P/E ratio of 12.50, a PEG ratio of 1.46 and a beta of 0.39. The stock has a fifty day moving average of $51.27 and a two-hundred day moving average of $51.62. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31. Bristol-Myers Squibb has a 12-month low of $47.58 and a 12-month high of $70.93.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.55 by $0.15. The firm had revenue of $11.48 billion during the quarter, compared to the consensus estimate of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The company’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.82 earnings per share. As a group, sell-side analysts expect that Bristol-Myers Squibb will post 6.63 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 5.00%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 62.18%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.